Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy

Quarta, C. C., Fontana, M., Damy, T., Catini, J., Simoneau, D., Mercuri, M., Garcia-Pavia, P., Maurer, M. S., & Palladini, G. (2022). Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy. Frontiers in Cardiovascular Medicine, 9. https://doi.org/10.3389/fcvm.2022.1073503
Authors:
C Cristina Quarta
Marianna Fontana
Thibaud Damy
Julia Catini
Damien Simoneau
Michele Mercuri
Pablo Garcia-Pavia
Mathew S Maurer
Giovanni Palladini
Affiliated Authors:
Mathew S Maurer
Author Keywords:
cardiac amyloidosis (ca)
cardiac amyloidosis—attr
cardiac light chain amyloidosis
future treatments
standard of care (soc)
treatment gaps
elink
Publication Type:
Article
Unique ID:
10.3389/fcvm.2022.1073503
PMID:
36606280
DOI:
10.3389/fcvm.2022.1073503
Journal:
Frontiers in Cardiovascular Medicine
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: